Effect of nasal salmon calcitonin on calcium and bone metabolism

Danish Medical Bulletin

Volumn 46, Issue 2, 1999, Pages 118-126

  Thamsborg, Gorm ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCITRIOL; CALCIUM; GLUCAGON; GONADORELIN; INSULIN; PARATHYROID HORMONE; VASOPRESSIN;

AREA UNDER THE CURVE; BONE MASS; BONE METABOLISM; CALCIUM METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALMON;

ABSORPTION; ADMINISTRATION, INTRANASAL; ADULT; BONE AND BONES; CALCITONIN; CALCIUM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032954142     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Thamsborg G, Storm TL, Brinch E, Sykulski R, Fogh-Andersen N, Holmegaard SN and Sørensen OH. The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. Calcif Tissue Int 1990; 46: 5-8.
2. Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK and Sørensen OH. Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 1991; 48: 302-307.
3. Thamsborg G, Storm TL, Daugaard H, Schifter S and Sørensen OH. Circulating levels of calciotropic hormones during treatment with nasal salmon calcitonin. Acta Endocrinol (Copenh) 1991; 125: 127-131.
4. Thamsborg G, Møller T, Kollerup G and Sørensen OH. Lack of effect of nasal salmon calcitonin on cell-mediated immunity. Bone Mineral 1993; 20: 245-249.
5. Thamsborg G, Skousgaard SG, Daugaard H, Schifter S, Kollerup G and Sørensen OH. Acute effects of nasal salmon calcitonin on calcium and bone metabolism. Calcif Tissue Int 1993; 53: 232-236.
6. Thamsborg G, Jensen JEB, Kollerup G, Hauge E, Melsen F and Sørensen OH. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996; 18: 207-212.
7. Copp DH, Cameron EC, Chency BA, Davidson AGF, Henze KG. Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962; 70: 638-649.
8. Foster GV, Baghdiantz A, Kumar MA, Slack E, Soliman HA, MacIntyre I. Thyroid origin of calcitonin. Nature 1964; 4939: 1303-1305.
9. Friedman J, Raisz LG. Thyrocalcitonin: Inhibitor of bone resorption in tissue culture. Science 1965; 150: 1465-1467.
10. Aliapoulios MA, Goldhaber P, Munson PL. Thyrocalcitonin inhibition of bone resorption induced by parathyroid hormone in tissue culture. Science 1966; 151: 330-331.
11. Shai F, Baker RK, Wallach S. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. J Clin Invest 1971: 50; 1927-1940.
12. Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974; 34: 1268-1274.
13. Wallach S, Cohn SH, Atkins HL, Ellis KJ, Kohberger R, Aloia JF, Zanzi I. Effect of salmon calcitonin on skeletal mass in osteoporosis. Cur Ther Res 1977; 22: 556-572.
14. Austin LA, Heath H. Calcitonin. Physiology and pathophysiology. NEJM 1981; 304: 269-278.
15. Peel NFA, Barrington NA, Smith TWD, Eastell R. Distal forearm fracture as risk factor for vertebral osteoporosis. BMJ 1994; 308: 1543-1544.
16. Mallmin H, Ljunghall S, Persson I, Naessén T, Krusemo UB, Bergstrøm R. Fracture of the distal forearm as a forecaster of subsequent hip fracture: A population-based cohort study with 24 years of follow up. Calcif Tissue Int 1993; 52: 269-272.
17. Owen RA, Melton LJ, Ilstrup DM, Johnson KA, Riggs BL. Colles' fracture and subsequent hip fracture risk. Clin Ortho Rel Res 1982; 171:37-43.
18. Andersson KE, Arner B. Effects of DDVAP, a synthetic analogue of vasopressin, in patients with central diabetes insipidus. Acta Med Scand 1972; 192: 21-27.
19. Pontiroli AE, Alberetto M, Secchi A, Dossie G, Bosi I, Pozza G. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects. BMJ 1982; 284: 303-306.
20. Fink G, Gennser G, Liedholm P, Thorell J. Comparison of plasma levels of LHRH in men after intravenous and intranasal administration. J Endocrinol 1974; 63: 351-360.
21. Pontiroli AE, Alberetto M, Pozza G. Intranasal glucagon raises blood glucose concentration in healthy volunteers. BMJ 1983; 287: 462-463.
22. Pontiroli AE, Alberetto M, Pozza G. Intranasal calcitonin and plasma calcium concentrations in normal subjects. BMJ 1985; 290: 1390-1391.
23. Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72: 344-349.
24. Tørring O, Bucht E, Sjøstedt U, Sjøberg HE. Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. Bone 1991; 12: 311-316.
25. Beveridge T, Niederer W, Nüesch E, Petrin A. Pharmacokinetic study with synthetic salmon calcitomin. Z Gastroenterol 1976; 10: 12-15.
26. Rowland M, Toler TN. Clinical pharmacokinetics. Concepts and applications. Williams and Wilkins 1995. Baltimore, Philadelphia, Hong Kong, London, Munich, Sydney, Tokyo pp. 127-128.
27. Tarquini B, Cavallini V, Cariddi A, Checchi M, Sorice V, Cecchettin M. Prominent circadian absorption of intranasal salmon calcitonin (SCT) in healthy subjects. Chronobiology Int 1988; 5: 149-152.
28. Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, Gomez F, Burckhardt P. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987; 41: 252-258.
29. Gennari C, Chierichetti SM, Vibelli C, Francini G, Maioli E, Gonnelli S. Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man. Cur Ther Res 1981; 30: 1024-1032.
30. Doppelt SH, Talmage RV. Calcitonin and the bone fluid compartment. Clin Orthop 1976; 118: 242-250.
31. Singer FR, Melvin KEW, Mills BG. Acute effects of calcitonin on osteoclasts in man. Clin Endocrinol 1976; 5: 333s-340s.
32. Cochran M. Peacock M, Sachs G, Nordin BEC. Renal effects of calcitonin. BMJ 1970; 1: 135-137.
33. Reginster JY, Denis D, Albert A, Franchimont P. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin by comparison with intramuscular or placebo injection in normal subjects. Bone Mineral 1987: 2; 133-140.
34. O'Doherty DP, Bickerstaff DR, McCloskey EV, Atkins R, Hamdy NAT, Kanis JA. A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci 1990; 78: 215-219.
35. Overgaard K, Riis BJ, Christiansen C, Pødenphant J, Johansen JS. Nasal calcitonin treatment of established osteoporosis. Clin Endocrinol 1989; 30: 435-442.
36. Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299: 477-479.
37. Meunier PJ, Delmas PD, Chaumet-Riffaud PD, Gozzo I, Duboeuf F, Chapuy MC, Guignard M. Intranasal salmon caicitonin for prevention of postmenopausal bone loss. A placebo-controlled study in 109 women. In: Christiansen C, Overgaard K. (eds.) Osteoporosis 1990. Proc 3rd Int Symp on Osteoporosis. Osteopress 1990, Copenhagen, pp. 1861-1867.
38. Fioretti P, Gambacciani M, Taponeco F, Melis GB, Capelli N, Spinetti A. Effects of continuous and cyclic nasal calcitonin administration in ovarieectomized women. Maturitas 1992; 15: 225-232.
39. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305: 556-561.
40. Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M. Lombardi A, Norbiato G, Ortolani S, Ricerca E, Romanini L, Subrizi S, Weinberg J, Yates AJ. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporosis Int 1993; Suppl. 3: S21-27.
41. Camporeale A, Agnusdei D, Zacchei F, Cepollaro C, Borracelli D, Gennari C. Treatment of postmenopausal osteoporosis with intranasal salmon calcitonin: Doses and cycles. In: Christiansen C, Riis BJ (eds.). Proc 4th Int Symp on Osteoporosis and Consensus Development Conference 1993. Handelstrykkeriet 1993, Ålborg, pp. 142-143.
42. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study. Calcif Tissue Int 1994; 55: 82-86.
43. Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CE. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33: 295-303.
44. Heersche JNM, Marcus R, Aurbach GD. Calcitonin and the formation of 3,5-AMP in bone and kidney. Endocrinology 1974; 94: 251-257.
45. Fiore CE, Romagnoli A, Foti R, Coppini A. Assessment of the biological activity of synthetic salmon calcitonin by intranasal administration in healthy voltnteers. Drugs Exptl Clin Res 1991; 17: 537-542.
46. Minkoff JR, Grant BF, Marcus R. Plasma cyclic AMP response to calcitonin: A potential clinical marker of turnover. Bone 1985; 6: 285-290.
47. Chabre O, Conklin BR, Lin HY, Lodish HF, Wilson E, Ives HE, Catanzariti L, Hemmings BA, Bourne HR. A recombinant calcitonin receptor independently stimulates 3,5-cyclic adenosine monophosphate and calcium/inositol phopsphate signaling pathways. Molecular Endocrinology 1992; 6: 551-556.
48. Frost HM. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Int 1969; 3: 211-237.
49. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodeling. Nature 1965; 206: 489-490.
50. Mundy GR. Bone resorption and turnover in health and disease. Bone 1987; 8: S9-S16.
51. Holtrop ME, Raisz LG, Simmons HA. The effects of parathyroid hormone, colchicine, and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture J Cell Biol 1974; 60: 346-355.
52. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FAO, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest 1986; 78: 355-360.
53. Taylor LM, Tertinegg I, Okuda A, Heersche JNM. Expression of calcitonin receptors during osteoclast differentiation in mouse metatarsals. J Bone Miner Res 1989; 4: 751-758.
54. Chambers TJ, Magnus CJ. Calcitonin alters behaviour of isolated osteoclasts. J Pathol 1982; 136: 27-39.
55. Chambers TJ, Fuller K, Darby JA. Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone. J Cell Physiol 1987; 132: 90-96.
56. Chambers TJ, McSheehy PMJ, Thomson BM, Fuller K. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 1985; 116: 234-239.
57. Feldman RS, Krieger NS, Tashjian AH. Effects of parathyroid hormone and calcitonin on osteoclast formation in vitro. Endocrinology 1980; 107: 1137-1143.
58. Morel G, Boivin G, David L, Dubois PM, Meunier PJ. Immunocytochemical evidence for endogenous calcitonin and parathyroid hormone in osteoblasts from the calvaria of neonatal mice. Cell Tissue Research 1985; 240: 89-93.
59. Farley JR, Wergedal JE, Hall SL, Herring S, Tarbaux NM. Calcitonin has direct effects on 3-H-thymidine incorporation and alkaline phosphatase activity in human osteoblast-line cells. Calcif Tissue Int 1991; 48: 297-301.
60. Ziegler R, Delling G. Effect of calcitonin on the regeneration of circumscribed hone defect (bored hole in the rat tibia). Acta Endocrinol 1972; 69: 497-506.
61. Ogawa T, Ono T, Tsuda M, Kawanishi Y. A novel flour in insoluble collagen: a cross-linking moiety in collagen molecule. Biochem Biophys Res Com 1982; 107: 1252-1257.
62. González D. Vega E, Ghiringhelli G, Mautelen C. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin. Calcif Tissue Int 1987; 41: 313-315.
63. Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. JBMR 1988; 3: 249-252.
64. Van Der Wiel HE, Lips P, Nauta J, Kwakkel G, Hazenberg G, Netelenbos JC, Van Der Vijgh WJF. Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: A double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover. JBMR 1993; 8: 1459-1465.
65. Bijvoet OLM, van der Sluys Veer J, de Vries HR, van Koppen ATJ. Natriuretic effect of calcitonin in man. NEJM 1971; 284: 681-688.
66. Beck Jensen JB, Sørensen HA, Kollerup G, Jensen LB, Sørensen OH. Biological variation of biochemical bone markers. Scand J Clin Lab Invest 1994; 54 (Suppl 219):36-39.
67. Reginster JY, Denis D, Deroisy R, Lecart MP, de Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. JBMR 1994; 9: 69-73.
68. Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone bone loss. Am J Med 1995; 98: 452-458.
69. Reginster JY, Albert A, Lecart MP, Lambelin P, Denis D, Deroisy R, Fontaine MA, Franchimont P. 1-Year controlled randomised trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987; II: 1481-1483.
70. Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R. An effective regimen of intransal salmon calcitonin in early postmenopausal bone losse. Calcif Tissue 1992; 50: 381-383.
71. MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, llealy MJR. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; ii: 900-902.
72. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM 1990; 322: 1265-1271.
73. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989; ii: 1469-1471.
74. Reginster JY, Christiansen C, Dequinze B, Deroisy R, Gaspard U, Taquet AN, Franchimont P. Effect of transdermal 17beta-estradiol and oral conjugated equine estrogens on biocehmical parameters of bone resorption in natural menopause. Calcif Tissue Int 1993; 53: 13-16.
75. Lufkin EG, Warmer HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdermal estrogen.Ann Intern Med 1992; 117: 1-9.
76. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce B. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. JBMR 1996; 11: 150-160.
77. Storm T, Steiniche T, Thamsborg G, Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for post-menopausal osteoporosis. JBMR 1993; 8: 199-208.
78. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989; 10: 313-320.
79. Eriksen EF, Kudsk H, Emmertsen, Mosekilde L, Melsen F. Reconstruction of the remodeling sequence in medullary thyroid carcinoma. Bone 1993; 14: 399-401.
80. Haddad JG, Couranz S, Avioli AV. Nondialyzable urinary hydroxyproline as an index for bone collagen formation. J Clin Endocrinol 1970; 30: 282-288.
81. Krane SM, Harris ED, Singer FR, Potts JT. Acute effects of calcitonin on bone formation in man. Metabolism 1973; 22: 51-58.
82. Mazess RB. On aging bone loss. Clin Orthop 1982; 165: 239-252.
83. Tørring O, Bucht E, Sjøberg O. Plasma calcitonin response to a calcium clamp; influence of sex and age. Horm Metab Res 1985; 17: 536-541.
84. Tiegs RD, Body JJ, Wahner HW, Barta J, Riggs BL, Heath H. Calcitonin secretion in postmenopausal osteoporosis. NEJM 1985; 312: 1097-1102.
85. Prince RL, Dick IM, Price RI. Plasma calcitonin levels are not lower than normal in osteoporotic women. J Clin Endocrinol Metab 1989; 68: 684-687.
86. Leggate J, Farish E, Fletcher CD, McIntosh W, Hart DM, Sommerville JM. Calcitonin and postmenopausal osteoporosis. Clin Endocrinol 1984; 20: 85-92.
87. Hurley DL, Tiegs RD, Wahner HW, Heath H. Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. NEJM 1987; 317: 537-54.
88. Jergas M, Genant HK. Current methods and recent advances in the diagnosis of osteoporosis. Arthritis Rheumatism 1993; 36: 1649-1662.
89. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Bhaskar Rao M, Steiger P, Richmond B, Chesnut CH. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM 1990; 323: 73-79.
90. Lieberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch EJ, Karpf DB. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. NEJM 1995; 333: 1437-1443.
91. Christiansen C, Riis BJ. 17beta-oestradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836-841.
92. Munk-Jensen N, Pors-Nielsen S, Obel EB, Bonne Eriksen P. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study. BMJ 1988; 296: 1150-1152.
93. Horsman A, Gallagher JC, Simpson M, Nordin BEC. Prospective trial of oestrogen and calcium in postmenopausal women. BMJ 1977; 2: 789-792.
94. Recker RR, Saville PD, Heaney RP. Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977; 87: 649-655.
95. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski E, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation on bone density in postmenopuasal women. NEJM 1990; 323: 878-883.
96. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. NEJM 1993; 328: 460-464.
97. Muff R, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis. Osteoporosis Int 1991; 1: 72-75.
98. Reginster JY, Gaspar S, Deroisy R, Zegels B, Franchimont P. Prevention of osteoporosis with nasal salmon calcitonin: Effect of anti-salmon calcitonin antibody formation. Osteoporosis Int 1993; 3: 261-264.
99. Mazzouli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtora C, Palummeri E, Cervellin GF, Gonnelli S, Francini G. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study. Calcif Tissue Int 1986; 38: 3-8.
100. Gennari C, Chierichetti SM, Bigazzi S, Fusi E, Gonnelli S, Ferrara R, Zacchei F. Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Cur Ther Res 1985; 38: 455-464.
101. Kollerup G, Hermann AP, Brixen K, Eindblad BE, Mosekilde L, Sørensen OH. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis. Calcif Tissue Int 1994; 54: 12-15.
102. Reginster JY, Jupsin I, Deroisy R, Biquet I, Franchimont N, Franchimont P. Prevention of postmenopausal bone loss by rectal calcitonin. Calcif Tissue Int 1995; 56: 539-542.
103. Werner JA, Gorton SJ, Raisz LG. Escape from inhibition of resorption in cultures of fetal bone treated with calcitonin and parathyroid hormone. Endocrinology 1972; 90: 752-759.
104. Tashjian Jr AH, Wright DR, Ivey JE, Pont A. Calcitonin binding sites in bone: Relationships to biological response and "escape". Recent Prog Horm Res 1978; 34: 285-334.
105. Ransjö M, Lerner UH. Calcitonin causes a sustained inhibition of protein kinase C-stimulated bone resorption in contrast to the transient inhibition of parathyroid hormone-induced bone resorption. Acta Endocrinol (Copenh) 1990; 123: 251-256.
106. Kraenzlin ME, Seibel MJ, Treschel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 1996; 58: 216-220.
107. Eriksen EF, Axelrod DW, Melsen F. Bone histomorphometry. An official publication of the American Society for Bone and Mineral Research. Raven Press 1994. New York.
108. Mosekilde L. Knoglevævets biologi. Fysiologiske, kliniske og farmakologiske aspekter af relationerne mellem struktur og funktion. CibaGeigy 1989. Copenhagen..
109. Cann CE, Genant HK, Kolb FO, Ettinger B. Quantitative computed tomography for prediction of vertebral fracture risk. Bone 1985; 6: 1-7.
110. 2 in normal adult subjects. Clin Endocrinol 1989; 30: 699-704.
111. Ceda GP, Denti L, Ceresini G, Rastelli G, Dotti C, Cavalieri S, Valenti G, Hoffman AR. Calcitonin inhibition of growth hormone-releasing hormone-induced GH secretion in normal men. Acta Endocrinol (Copenh) 1989; 120: 416-422.
112. Lengyel AMJ, Toledo ALG, Czepielewski MA, Vieira JGH, Chacra AR. Calcitonin suppresses growth hormone (GH) response to growth hormone-releasing hormone (GHRH) in man. J Endocrinol Invest 1989; 12: 25-29.
113. Giugliano D. Calcitonin and the human endocrine pancreas. Biomed Pharmacother 1984; 38: 273-277.
114. Passariello N, Giugliano D, Sgambato S, Torella R, D'Onofrio F. Calcitonin, a diabetogenic hormone. J Clin Endocrinol Metab 1981; 53: 318-323.
115. Reeve J, Meunier PJ, Parsons JA et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ 1980; 280: 1340-1344.
116. Galante L, Colston KW, MacAuley SJ, MacIntyre I. Effect of calcitonin on vitamin D metabolism. Nature 1972; 238: 271-273.
117. 3-1 alfa-hydroxylase in proximal straight tubule of rat kidney. Nature 1981; 291: 327-329.
118. Jaeger P, Jones W, Clemens TL, Hayslett JP. Evidence that calcitonin stimulates 1,25-dihydroxyvitamin D production and intestinal absorption of calcium in vivo. J Clin Invest 1986; 78: 456-461.
119. Emmertsen K, Melsen F, Mosekilde L, Lund Bi, Lund Bj, Sørensen OH, Nielsen HE, Sølling H, Hansen HH. Altered vitamin D metabolism and bone remodeling in patients with medullary thyroid carcinoma and hypercalcitoninemia. Metab Bone Dis Rel Res 1981; 4: 17-23.
120. Morimoto S, Miyauchi A, Fukuo K, Imanaka S, Yamamoto H, Tsuchiya H, Koh E, Yukuwa S, Onishi T, Avioli LV, Kumahara Y. Eel calcitonin suppresses plasma human calcitonin levels in medullary carcinoma of the thyroid. Clinical Science 1986; 70: 333-338.
121. Hillyard CJ, Cooke TJC, Coombes RC, Evans IMA, Macintyre I. Normal plasma calcitonin: Circadian variation and response to stimuli. Clin Endocrin 1977; 6: 291-298.
122. Krane SM, Amento EP, Bhan AK, Goldring MB, Goldring SR, Stephenson ML, Upchurch KS. Potential role of immune cells in bone cell function. In: Cecchettin M, Segre G (eds.) Calciotropic hormones and calcium metabolism. Elsevier Science Publisher B.V. 1986 pp. 31-40.
123. Watrous DA, Andrews BS. The metabolism and immunology of bone. Seminars in Arthritis and Rheumatism. 1989; 19: 45-65.
124. Marx SJ, Aurbach GD. Calcitonin receptors on cultured human lymphocytes. J Biol Chem 1974; 249: 6812-6816.
125. Aida S, Okawa-Takatsuji M, Aotsuka S, Shimoji K, Yokohari R. Calcitonin inhibits production of immunoglobulins, rheumatoid factor and interleukin-1 by mononuclear cells from patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53: 247-249.
126. Abdullahi SE, Arrigoni Martelli E, Bramm E, Franco E, Velo GP. Effect of calcitonin on different inflammatory models. Agents Actions 1977; 7: 533-538.
127. Adami S, Suppi R, Residori M, Braga V, Zamboni M, LoCasio V. Intramuscular administration of salmon calcitonin impairs delayed cutaneous hypersensitivity. Bone Mineral 1988; 4: 91-94.
128. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. NEJM 1993; 328: 1747-1752.
129. Rizzato G, Schiraldi G, Tosi G, Locicero S, Montemurro L, Zanni D, Sisti S. Administration of salmon calcitonin nasal spray for long-term treatment of corticosteroid-induced osteoporosis. A preliminary report. Cur Ther Res 1989; 45: 761-766.
130. Sileghem A, Geusens P, Dequecker J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritris. Ann Rheum Dis 1992; 51: 761-764.